Literature DB >> 9262376

Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum luminal proteins.

A E Cribb1, L R Pohl, S P Spielberg, J S Leeder.   

Abstract

Sulfonamide antimicrobials cause a delayed-onset, hypersensitivity-type syndrome characterized by fever, skin rash and multiorgan toxicity occurring 7 to 14 days after initiation of therapy. The pathogenesis is believed to be immune-mediated. We investigated whether patients with delayed-onset sulfonamide hypersensitivity reactions had antibodies recognizing hapten-microsomal protein conjugates and/or native microsomal proteins. By immunoblotting using rat liver as a source of microsomal protein, 17 of 21 patients had antibodies recognizing one or more of three native endoplasmic reticulum proteins of 55 kDa (14 of 21 patients), 80 kDa (4 of 21 patients) or 96 kDa (3 of 21 patients) in size on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. No control subjects (n = 11) and only 1 of 18 patients with adverse events not consistent with sulfonamide hypersensitivity reactions had antibodies against these microsomal proteins under the conditions used. Only 1 patient had antibodies that recognized the sulfonamide hapten, sulfamethoxazole. The 55-kDa protein was identified as protein disulfide isomerase. The 80-kDa protein was identified as grp78. The 96-kDa protein was not identified. Delayed-onset sulfonamide hypersensitivity reactions are therefore primarily associated with antibodies recognizing specific protein epitopes and not anti-drug antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262376

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

Review 1.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

2.  Prevalence and Risk Factors for Sulfadoxine Antibody Among Patients Undergoing Treatment for Malaria in Benin City, Nigeria.

Authors:  Kingsley Ikuoyogie; Helen Oroboghae Ogefere; Richard Omoregie
Journal:  Oman Med J       Date:  2017-05

3.  Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Authors:  Jennifer L Goldman; Yakov M Koen; Steven A Rogers; Kelin Li; James S Leeder; Robert P Hanzlik
Journal:  Drug Metab Dispos       Date:  2016-07-25       Impact factor: 3.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.